IPCALAB Stock Overview
A pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,404.40 |
| 52 Week High | ₹1,755.90 |
| 52 Week Low | ₹1,052.00 |
| Beta | 0.36 |
| 1 Month Change | 4.26% |
| 3 Month Change | -9.00% |
| 1 Year Change | 3.85% |
| 3 Year Change | 36.30% |
| 5 Year Change | 83.13% |
| Change since IPO | 3,595.79% |
Recent News & Updates
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 16
Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Jan 10Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
Dec 20Recent updates
Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 16Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Jan 10Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
Dec 20
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Dec 12 Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
Nov 17Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Sep 10Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
Jun 07Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 24Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Shareholder Returns
| IPCALAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 8.5% | 6.4% | 6.5% |
| 1Y | 3.9% | 14.6% | 3.6% |
Return vs Industry: IPCALAB underperformed the Indian Pharmaceuticals industry which returned 12.9% over the past year.
Return vs Market: IPCALAB exceeded the Indian Market which returned 2.1% over the past year.
Price Volatility
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.9% |
Stable Share Price: IPCALAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: IPCALAB's weekly volatility (6%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 17,335 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology.
Ipca Laboratories Limited Fundamentals Summary
| IPCALAB fundamental statistics | |
|---|---|
| Market cap | ₹356.30b |
| Earnings (TTM) | ₹7.29b |
| Revenue (TTM) | ₹87.27b |
48.8x
P/E Ratio4.1x
P/S RatioIs IPCALAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCALAB income statement (TTM) | |
|---|---|
| Revenue | ₹87.27b |
| Cost of Revenue | ₹30.28b |
| Gross Profit | ₹56.99b |
| Other Expenses | ₹49.69b |
| Earnings | ₹7.29b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 28.75 |
| Gross Margin | 65.30% |
| Net Profit Margin | 8.36% |
| Debt/Equity Ratio | 14.8% |
How did IPCALAB perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield14%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 13:31 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipca Laboratories Limited is covered by 49 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |